Dynavax Technologies (DVAX) Stock Price
Dynavax Technologies Price
Revenue has compounded at 16.7% per year over the past 19 years to 277.25 M USD. Earnings per share have declined at 33.8% per year over the last 3 years. Dynavax Technologies's net margin stands at 9.9%, up from -161.6% several years earlier. Analysts set a median price target of 20.91 USD, implying 34.9% above the current price. Of 9 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 66% above its 52-week low.
Dynavax Technologies stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Dynavax Technologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Dynavax Technologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Dynavax Technologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Dynavax Technologies Price |
|---|---|
| 2/9/2026 | 15.50 USD |
| 2/6/2026 | 15.50 USD |
| 2/5/2026 | 15.49 USD |
| 2/4/2026 | 15.51 USD |
| 2/3/2026 | 15.48 USD |
| 2/2/2026 | 15.49 USD |
| 1/30/2026 | 15.49 USD |
| 1/29/2026 | 15.48 USD |
| 1/28/2026 | 15.48 USD |
| 1/27/2026 | 15.48 USD |
| 1/26/2026 | 15.52 USD |
| 1/23/2026 | 15.51 USD |
| 1/22/2026 | 15.65 USD |
| 1/21/2026 | 15.68 USD |
| 1/20/2026 | 15.68 USD |
| 1/16/2026 | 15.63 USD |
| 1/15/2026 | 15.62 USD |
| 1/14/2026 | 15.60 USD |
| 1/13/2026 | 15.72 USD |
| 1/12/2026 | 15.68 USD |
| 1/9/2026 | 15.41 USD |
| 1/8/2026 | 15.41 USD |
| 1/7/2026 | 15.41 USD |
| 1/6/2026 | 15.43 USD |
| 1/5/2026 | 15.41 USD |
| 1/2/2026 | 15.38 USD |
| 12/31/2025 | 15.38 USD |
| 12/30/2025 | 15.37 USD |
| 12/29/2025 | 15.37 USD |
| 12/26/2025 | 15.38 USD |
| 12/24/2025 | 15.38 USD |
| 12/23/2025 | 11.13 USD |
| 12/22/2025 | 11.16 USD |
| 12/19/2025 | 10.86 USD |
| 12/18/2025 | 10.87 USD |
| 12/17/2025 | 10.79 USD |
| 12/16/2025 | 10.78 USD |
| 12/15/2025 | 10.85 USD |
| 12/12/2025 | 10.80 USD |
| 12/11/2025 | 10.86 USD |
| 12/10/2025 | 10.90 USD |
| 12/9/2025 | 10.89 USD |
| 12/8/2025 | 10.97 USD |
| 12/5/2025 | 10.89 USD |
| 12/4/2025 | 10.96 USD |
| 12/3/2025 | 10.97 USD |
| 12/2/2025 | 10.88 USD |
| 12/1/2025 | 10.71 USD |
| 11/28/2025 | 11.37 USD |
| 11/26/2025 | 11.43 USD |
| 11/25/2025 | 11.47 USD |
| 11/24/2025 | 11.44 USD |
| 11/21/2025 | 11.18 USD |
| 11/20/2025 | 10.80 USD |
| 11/19/2025 | 11.05 USD |
| 11/18/2025 | 11.23 USD |
| 11/17/2025 | 11.14 USD |
| 11/14/2025 | 11.06 USD |
| 11/13/2025 | 11.16 USD |
| 11/12/2025 | 11.26 USD |
| 11/11/2025 | 11.27 USD |
| 11/10/2025 | 11.04 USD |
| 11/7/2025 | 10.83 USD |
| 11/6/2025 | 10.99 USD |
| 11/5/2025 | 10.30 USD |
| 11/4/2025 | 10.05 USD |
| 11/3/2025 | 10.19 USD |
| 10/31/2025 | 10.26 USD |
| 10/30/2025 | 10.40 USD |
| 10/29/2025 | 10.30 USD |
| 10/28/2025 | 10.46 USD |
| 10/27/2025 | 10.49 USD |
| 10/23/2025 | 10.19 USD |
| 10/22/2025 | 10.15 USD |
| 10/21/2025 | 10.12 USD |
| 10/20/2025 | 10.07 USD |
| 10/16/2025 | 9.80 USD |
| 10/15/2025 | 9.93 USD |
| 10/14/2025 | 9.83 USD |
| 10/13/2025 | 10.01 USD |
| 10/9/2025 | 10.35 USD |
| 10/8/2025 | 10.18 USD |
| 10/7/2025 | 10.14 USD |
| 10/6/2025 | 10.14 USD |
| 10/2/2025 | 10.10 USD |
| 10/1/2025 | 10.28 USD |
| 9/30/2025 | 9.93 USD |
| 9/29/2025 | 9.66 USD |
| 9/25/2025 | 9.73 USD |
| 9/24/2025 | 9.96 USD |
| 9/23/2025 | 9.59 USD |
| 9/22/2025 | 9.69 USD |
| 9/18/2025 | 9.75 USD |
| 9/17/2025 | 9.57 USD |
| 9/16/2025 | 9.70 USD |
| 9/15/2025 | 9.36 USD |
| 9/11/2025 | 9.74 USD |
| 9/10/2025 | 9.72 USD |
| 9/9/2025 | 9.92 USD |
| 9/8/2025 | 9.70 USD |
| 9/4/2025 | 9.98 USD |
| 9/3/2025 | 10.13 USD |
| 9/2/2025 | 9.91 USD |
| 8/28/2025 | 10.27 USD |
| 8/27/2025 | 10.26 USD |
| 8/26/2025 | 10.44 USD |
| 8/25/2025 | 10.39 USD |
Dynavax Technologies Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Dynavax Technologies Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.00 | 4.00 | 11.00 | – | 8.00 | 35.00 | 46.00 | 439.00 | 722.00 | 232.00 | 277.00 | – | – | 430.00 | 515.00 | 565.00 |
| – | -63.64 | 175.00 | – | – | 337.50 | 31.43 | 854.35 | 64.46 | -67.87 | 19.40 | – | – | – | 19.77 | 9.71 |
| 100.00 | 100.00 | 100.00 | – | -162.50 | 42.86 | 69.57 | 60.36 | 63.71 | 78.45 | 81.95 | – | – | 81.95 | 81.95 | 81.95 |
| 11.00 | 4.00 | 11.00 | 227.00 | -13.00 | 15.00 | 32.00 | 265.00 | 460.00 | 182.00 | 227.00 | 227.00 | 227.00 | 352.38 | 422.04 | 463.01 |
| -91.00 | -105.00 | -110.00 | -96.00 | -153.00 | -138.00 | -57.00 | 145.00 | 283.00 | -37.00 | -4.00 | -16.00 | -17.00 | -20.00 | -24.00 | -26.00 |
| -827.27 | -2,625.00 | -1,000.00 | – | -1,912.50 | -394.29 | -123.91 | 33.03 | 39.20 | -15.95 | -1.44 | – | – | -4.65 | -4.66 | -4.60 |
| -90.00 | -106.00 | -112.00 | -95.00 | -158.00 | -152.00 | -75.00 | 76.00 | 293.00 | -6.00 | 27.00 | 38.00 | 51.00 | 76.00 | 125.00 | 147.00 |
| 36.36 | 17.78 | 5.66 | -15.18 | 66.32 | -3.80 | -50.66 | -201.33 | 285.53 | -102.05 | -550.00 | 40.74 | 34.21 | 49.02 | 64.47 | 17.60 |
| 26.30 | 38.43 | 38.54 | 61.01 | 62.69 | 84.00 | 110.29 | 124.95 | 151.73 | 133.28 | 153.02 | 153.02 | 153.02 | 153.02 | 153.02 | 153.02 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Dynavax Technologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Dynavax Technologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Dynavax Technologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Dynavax Technologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Dynavax Technologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Dynavax Technologies stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Dynavax Technologies Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Dynavax Technologies business model & stock analysis
Dynavax Technologies SWOT Analysis
Strengths
Dynavax Technologies Corp possesses several strengths that contribute to its success:
Dynavax is renowned for its cutting-edge biotechnology solutions which have led to the development of advanced vaccines to combat serious diseases.
The company's dedicated R&D team consistently delivers breakthrough solutions, allowing Dynavax to maintain a competitive edge in the biotech industry.
Dynavax possesses a substantial intellectual property portfolio, safeguarding its innovative technologies and providing a barrier to entry for potential competitors.
Weaknesses
Despite its strengths, Dynavax Technologies Corp faces certain weaknesses that may present challenges:
Dynavax relies heavily on partnerships with other pharmaceutical companies for the distribution and commercialization of its products, which may limit its control over market strategies and profit margins.
The company currently has a relatively limited portfolio of products, which exposes it to greater risks if a product fails to gain regulatory approval or faces strong competition.
Opportunities
Dynavax Technologies Corp has opportunities to explore in its industry:
The increasing global focus on preventive healthcare and vaccination programs creates a significant market opportunity for Dynavax to expand its product offerings and revenue streams.
Continuous advancements in biotechnology provide an opportunity for Dynavax to leverage its expertise and develop new innovative solutions to address unmet medical needs.
Threats
Dynavax Technologies Corp faces various threats that may impact its growth and profitability:
The biotech industry is highly competitive, with numerous established players and emerging companies. Dynavax must actively compete to maintain its market share.
Strict regulations and compliance requirements in the healthcare sector pose challenges for Dynavax, necessitating substantial investments in clinical trials and regulatory processes.
Dynavax Technologies Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Dynavax Technologies Segments
Dynavax Technologies Revenue by Segment (1/5)
Max
Details
Dynavax Technologies Revenue by Segment (2/5)
Max
Details
Dynavax Technologies Revenue by Segment (3/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Dynavax Technologies Revenue by Segment (4/5)
Max
Details
Dynavax Technologies Revenue by Segment (5/5)
Max
Details
Dynavax Technologies Revenue by Region
3 Years
Max
Details
Dynavax Technologies Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Dynavax Technologies historical P/E ratio, EBIT multiple, and P/S ratio
Dynavax Technologies annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Dynavax Technologies shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Dynavax Technologies stock splits
Current Dynavax Technologies forecasts and price targets in August 2026
Analyst Price Targets 2026Dynavax Technologies Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 12/24/2025 | Downgrade | OutperformMarket Perform | – | |
| 8/22/2025 | Maintained | Market Outperform | – | |
| 8/8/2025 | Maintained | Market Outperform | – | |
| 5/7/2025 | Maintained | Market Outperform | – | |
| 4/17/2025 | Maintained | Sell | 51 | |
| 2/21/2025 | Maintained | Buy | – | |
| 2/21/2025 | Maintained | Market Outperform | – | |
| 2/11/2025 | Downgrade | NeutralSell | 51 | |
| 1/14/2025 | Maintained | Buy | – | |
| 11/8/2024 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Dynavax Technologies Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/5/2026 | 0.17USD | - | 107.62 MUSD | - | 2026 Q2 |
| 5/4/2026 | 0.08USD | - | 86.37 MUSD | - | 2026 Q1 |
| 2/18/2026 | 0.04USD | - | 81.87 MUSD | - | 2025 Q4 |
| 4/30/2024 | 0.02USD | - | 66.31 MUSD | - | 2024 Q1 |
| 2/21/2024 | 0.00USD | - | 59.32 MUSD | - | 2023 Q4 |
| 8/2/2023 | -0.19USD | - | 80.49 MUSD | - | 2023 Q2 |
| 5/3/2023 | -0.20USD | - | 74.07 MUSD | - | 2023 Q1 |
| 2/27/2023 | 0.33USD | - | 161.50 MUSD | - | 2022 Q4 |
| 11/3/2022 | 0.33USD | - | 161.80 MUSD | - | 2022 Q3 |
| 8/4/2022 | 0.22USD | - | 153.26 MUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Dynavax Technologies stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Dynavax Technologies shareholder structure
| % | Name |
|---|---|
13.89721% | |
13.83387% | |
7.39326% | |
5.62627% | |
3.79029% | |
3.33834% |
Dynavax Technologies Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
14.20% | SEC ↗ | |
13.92% | SEC ↗ | |
13.92% | SEC ↗ | |
13.92% | SEC ↗ | |
13.92% | SEC ↗ | |
13.92% | SEC ↗ | |
13.70% | SEC ↗ | |
13.50% | SEC ↗ | |
13.41% | SEC ↗ | |
9.40% | SEC ↗ |
Dynavax Technologies Executives and Management Board
15 members · avg. age 62 · 20 % women
Mr. Ryan Spencer (47)
Chief Executive Officer, Director · since 2019
8.21 M USD
Management
Mr. David Novack (63)
President, Chief Operating Officer
Mr. John Slebir (59)
Senior Vice President, General Counsel
Ms. Kelly MacDonald (41)
Chief Financial Officer, Senior Vice President
Dr. Robert Janssen (71)
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Mr. Joseph Metzinger (41)
Vice President, Chief Accounting Officer
Mr. Paul Cox
Vice President, Investor Relations and Corporate Communications · since 2025
Board of Directors
Mr. Scott Myers (58)
Independent Chairman of the Board
Dr. Peter Paradiso (74)
Independent Director
Dr. Daniel Kisner (78)
Independent Director
Ms. Elaine Sun (54)
Independent Director
Dr. Francis Cano (80)
Independent Director
Mr. Brent MacGregor (61)
Independent Director
Dynavax Technologies Supply Chain
Dynavax Technologies Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.73 | 0.50 | 0.77 | ||
| 2 | 0.84 | 0.73 | 0.62 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.87 | — | — | ||
| 2 | 0.77 | 0.18 | 0.02 |
Frequently asked questions about Dynavax Technologies
The business model of Dynavax Technologies Corp focuses on developing and commercializing innovative vaccines to address critical unmet medical needs. As a biopharmaceutical company, Dynavax utilizes its expertise in immunology to create novel vaccines that target diseases such as hepatitis B, pertussis, and the flu. Through strategic partnerships and collaborations, the company aims to advance its vaccine candidates and bring them to market. Dynavax's business model is centered around research and development, regulatory approvals, and successful commercialization of their vaccine products to improve public health and provide value to shareholders.
Dynavax Technologies Corp is primarily active in the biotechnology industry. As a reputable company in the stock market, Dynavax Technologies Corp focuses on developing and commercializing novel vaccines and therapeutics. With its innovative approaches to immunology, the company addresses pressing medical needs in areas such as infectious diseases, oncology, and autoimmune disorders. With a strong presence in the biotechnology sector, Dynavax Technologies Corp consistently strives to revolutionize the healthcare industry through groundbreaking advancements.
The main competitors of Dynavax Technologies Corp in the market are companies like GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co., Inc., and Pfizer Inc. These pharmaceutical giants operate in similar fields as Dynavax and offer competitive products and services. However, Dynavax Technologies Corp distinguishes itself through its innovative approach, cutting-edge technologies, and continuous research and development efforts. As a result, Dynavax has successfully carved out its space in the market, offering unique solutions and contributing to advancements in the healthcare industry.
Dynavax Technologies Corp is a leading biopharmaceutical company specializing in the discovery, development, and commercialization of innovative vaccines and immunotherapies. Established in 1996, Dynavax has a rich history of pioneering research in the field of immunology. The company has made significant advancements in novel vaccine platforms, including DNA-based vaccines and Toll-like Receptor (TLR) agonists. With a strong focus on improving patient outcomes, Dynavax has successfully developed and brought to market several FDA-approved vaccines, such as HEPLISAV-B® for hepatitis B. Dynavax Technologies Corp continues to drive advancements in the field of immunotherapy, aiming to combat infectious diseases and achieve better global health outcomes.
Dynavax Technologies Corp has achieved several significant milestones. One notable milestone is the FDA approval of their vaccine HEPLISAV-B for the prevention of hepatitis B infection in adults. This approval marked a major breakthrough, as HEPLISAV-B demonstrated superior efficacy compared to existing vaccines. Additionally, the company successfully completed clinical trials for SD-101, an investigational cancer immunotherapy. These trials demonstrated promising results, potentially opening new avenues for treating various cancers. Furthermore, Dynavax Technologies Corp secured partnerships with renowned pharmaceutical companies, facilitating the development and commercialization of their innovative products. These achievements highlight the company's dedication to advancing healthcare solutions and driving growth in the biopharmaceutical industry.
Dynavax Technologies Corp is primarily present in the United States.
Dynavax Technologies Corp represents values of innovation, dedication, and excellence in the biotechnology industry. With a strong corporate philosophy centered around improving patient outcomes and enhancing global health, Dynavax is committed to developing and commercializing novel vaccines for the prevention and treatment of infectious diseases. By leveraging cutting-edge science and advanced technologies, the company aims to address unmet medical needs and contribute to the well-being of communities worldwide. Dynavax Technologies Corp continuously strives to provide groundbreaking solutions and foster a culture of collaboration and scientific rigor in its pursuit of improving public health.
Analysts currently set an average price target of 20.91 USD for the Dynavax Technologies stock (median: 20.91 USD), implying +34.9 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Dynavax Technologies stock: 7 recommend buying, 2 holding and 0 selling.
Converted at the current exchange rate, the Dynavax Technologies share trades at 13.27 EUR (15.50 USD).
The Dynavax Technologies share (DVAX) is listed on 7 stock exchanges, including: NASDAQ (DVAX), Frankfurt (DYF1.F), München (DYF1.MU), Düsseldorf (DYF1.DU), London (0IDA.L), London (0IDA.L), SIX (Zürich) (DYF1.SW).
Dynavax Technologies Corp is a biopharmaceutical company that focuses on the development of vaccines for various diseases. The company is headquartered in Emeryville, California and was founded in 1996. Dynavax has become a leading provider of vaccines in the market in recent years. The business model of Dynavax includes research, development, manufacturing, and marketing of vaccines for various diseases. One of its key products is the Heplisav-B vaccine. Heplisav-B is a Hepatitis B vaccine approved for the prevention of Hepatitis B infections in adults. In addition, the company also has other products in development. These include vaccines for rabies, pneumonia, and Hepatitis C. Dynavax has also developed a platform technology called SICCAR, which enables the production of fast-acting vaccines. Dynavax has different divisions focused on the development of vaccines for different diseases. The main divisions of the company are Hepatitis B vaccines, rabies vaccines, pneumonia vaccines, and Hepatitis C vaccines. Additionally, Dynavax is also developing vaccines for other diseases such as cancer. Dynavax's business model also includes partnerships with other companies for the joint development and marketing of vaccines. The company collaborates with major pharmaceutical companies such as GlaxoSmithKline and AstraZeneca to develop vaccines for various diseases. Dynavax also utilizes its platform technology to develop vaccines for partner companies. The company also relies on geographical expansion to expand the market for its products. Dynavax has opened branches in Europe and Asia to strengthen its presence in the global market. This has allowed the company to sell its products in other parts of the world and attract new customers. Overall, Dynavax's business model is focused on the development and marketing of vaccines for various diseases. The company relies on a wide range of products and offers a platform technology to enable faster vaccine development. Dynavax has also embraced partnerships and geographical expansion to expand its market share and broaden the opportunities for its products.
The revenue cannot currently be calculated for Dynavax Technologies.
The expected profit of Dynavax Technologies is 51.16 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Dynavax Technologies is currently 46.36. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dynavax Technologies stock.
The P/S cannot be calculated for Dynavax Technologies currently.
The Eulerpool Quality Score for Dynavax Technologies is 3/10.
The ISIN of Dynavax Technologies is US2681582019. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Dynavax Technologies is A12EV9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Dynavax Technologies is DVAX. The ticker symbol is used to trade Dynavax Technologies shares on the stock exchange.
Dynavax Technologies paid dividends every year for the past 0 years.
Dynavax Technologies is assigned to the 'Health' sector.
The dividends of Dynavax Technologies are distributed in USD.
Dynavax Technologies stock
Dynavax Technologies Peer Group
Dynavax Technologies Ticker
Dynavax Technologies FIGI
All fundamentals and in-depth analysis of Dynavax Technologies
Our stock analysis for Dynavax Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dynavax Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.